Risk, management of VTE in bevacizumab-treated colorectal cancer
the ONA take:
Risk of venous thromboembolisms (VTEs) in patients with cancer can be high, according to researchers in British Columbia, Canada. This patient population is already predisposed to prothrombotic states.
The researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.
Using a cohort of 499 evaluable patients, the researchers found 81 patients developed VTEs after receiving bevacizumab, and nine patients experienced more than one event. Those patients who experienced VTEs were more likely to have pre-existing cardiovascular diseases, resection of the primary cancer, high pre-chemotherapy platelet count, and received more than 12 bevacizumab cycles.
The researchers conclude the risk of VTEs can be high in patients receiving bevacizumab, especially in those with specific pretreatment risk factors and in those who received more of the drug.
Researchers assessed the incidence of VTEs in a cohort of patients with metastatic colorectal cancer (mCRC) who were treated with bevacizumab.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|